美国 · SEC FORM 4
Corbus Pharmaceuticals Holdings, Inc.
CRBP · Nasdaq · CIK 0001595097 · Healthcare · Biotechnology
内部人信号
当前没有活跃买入信号
3 qualifying P purchase groups
当前 180 天评分窗口
17 同一窗口内观察到的 Form 4 交易行
6 sales · 8 期权、代扣税、授予、赠与或其他交易行
最近一次合资格买入2026-08-11 · Saxena Nishant C · $25.0K
为什么没有活跃信号？
买入活动存在
近期买入3 qualifying line group(s)
近期卖出中等
买入信号状态未激活
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
Cluster未计算
买入规模未计算
角色未计算
近期性未计算
确信度未计算
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
AprMayJunJulAugSepOct
Saxena Nishant CChief Business Officer
○●●●
Kung WinstonDirector
○▼
Jenkins John KennethDirector
○▼
Altmeyer AnneDirector
○▼
Ben YongDirector
○▼
Jacques Rachelle SuzanneDirector
○
● 买入▼ 卖出○ 其他
Showing the six most active owners; 4 additional owner(s) remain in Form 4 申报证据.
买方广度与集中度
合资格买方1
买入集中度100%最大买方： Saxena Nishant C · $126.2K
聚集买入 · 15天1 insider峰值活动： 2026-06-02–2026-06-03
Roles in the peak window: Chief Business Officer. Concentration uses priced qualifying P lines only and does not change the saved score.
信号历史
暂无已记录的活跃信号快照
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2026-08-11 · Saxena Nishant C.
近期 Form 4 活动
3买入
17卖出
16其他 Form 4 交易行
30SEC 申报 · 365天
买入3 qualifying P line(s) · 180 days
卖出6 sale line(s) · 仅供背景
其他8 exercise / withholding / award / gift / other lines
10b5-1／计划交易Not assessed
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 3,054,964
- 上期报告
- 2,759,255
- 日均成交量
- 791,386
- 回补天数
- 3.9
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-08-11 | Saxena Nishant C | 买入 (P) | Common Stock, par value $0.0001 per share | 2,600 | USD 9.63 | USD 25,038 | SEC 申报 ↗ |
| 2026-06-03 | Saxena Nishant C | 买入 (P) | Common Stock, par value $0.0001 per share | 9,000 | USD 7.58 | USD 68,220 | SEC 申报 ↗ |
| 2026-06-02 | Saxena Nishant C | 买入 (P) | Common Stock, par value $0.0001 per share | 4,500 | USD 7.33 | USD 32,985 | SEC 申报 ↗ |
| 2024-09-20 | Chen Bihua; Cormorant Asset Management, LP; Cormorant Global Healthcare Master Fund, LP | 买入 (P) | Common Stock | 350,000 | USD 20.01 | USD 7,004,060 | SEC 申报 ↗ |
| 2024-03-08 | Chen Bihua; Cormorant Asset Management, LP; Cormorant Global Healthcare Master Fund, LP | 买入 (P) | Common Stock | 300,000 | USD 44.38 | USD 13,314,193 | SEC 申报 ↗ |
| 2024-03-07 | Chen Bihua; Cormorant Asset Management, LP; Cormorant Global Healthcare Master Fund, LP | 买入 (P) | Common Stock | 250,000 | USD 40.05 | USD 10,013,367 | SEC 申报 ↗ |
| 2024-02-02 | Chen Bihua; Cormorant Asset Management, LP; Cormorant Global Healthcare Master Fund, LP | 买入 (P) | Common Stock | 750,000 | USD 19.00 | USD 14,250,000 | SEC 申报 ↗ |
| 2024-01-26 | Chen Bihua; Cormorant Asset Management, LP; Cormorant Global Healthcare Master Fund, LP | 买入 (P) | Common Stock | 282,632 | USD 32.24 | USD 9,111,941 | SEC 申报 ↗ |
| 2022-08-10 | Millian Craig Stuart | 买入 (P) | Common Stock | 5,000 | USD 0.25 | USD 1,250 | SEC 申报 ↗ |
| 2022-08-10 | Cohen Yuval | 买入 (P) | Common Stock | 3,800 | USD 0.26 | USD 988 | SEC 申报 ↗ |
| 2022-08-10 | Moran Sean F. | 买入 (P) | Common Stock | 20,000 | USD 0.26 | USD 5,200 | SEC 申报 ↗ |
| 2022-05-16 | Moran Sean F. | 买入 (P) | Common Stock | 12,000 | USD 0.30 | USD 3,600 | SEC 申报 ↗ |
| 2022-05-16 | Cohen Yuval | 买入 (P) | Common Stock | 10,500 | USD 0.25 | USD 2,625 | SEC 申报 ↗ |
| 2022-03-10 | Millian Craig Stuart | 买入 (P) | Common Stock | 10,000 | USD 0.37 | USD 3,700 | SEC 申报 ↗ |
| 2022-03-10 | Moran Sean F. | 买入 (P) | Common Stock | 15,000 | USD 0.37 | USD 5,550 | SEC 申报 ↗ |
Form 4 申报证据
36 transaction lines in the latest 365-day window; 138 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-14 | Ben Yong | 卖出 (S) | Common Stock, par value $0.0001 per share | 2,000 | USD 7.84 | USD 15,680 | SEC 申报 ↗ |
| 2026-08-16 | Nicacio Leonardo Viana | 奖励／授予 (A) | Common Stock, par value $0.0001 per share | 58,333 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-08-11 | Saxena Nishant C | 买入 (P) | Common Stock, par value $0.0001 per share | 2,600 | USD 9.63 | USD 25,038 | SEC 申报 ↗ |
展开近期 Form 4 证据 (30 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-14 | Ben Yong | 卖出 (S) | Common Stock, par value $0.0001 per share | 2,000 | USD 7.84 | USD 15,680 | SEC 申报 ↗ |
| 2026-08-16 | Nicacio Leonardo Viana | 奖励／授予 (A) | Common Stock, par value $0.0001 per share | 58,333 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-08-11 | Saxena Nishant C | 买入 (P) | Common Stock, par value $0.0001 per share | 2,600 | USD 9.63 | USD 25,038 | SEC 申报 ↗ |
| 2026-08-07 | Moran Sean F. | 卖出 (S) | Common Stock, par value $0.0001 per share | 12,000 | USD 10.08 | USD 120,960 | SEC 申报 ↗ |
| 2026-08-07 | Cohen Yuval | 卖出 (S) | Common Stock, par value $0.0001 per share | 17,000 | USD 10.08 | USD 171,360 | SEC 申报 ↗ |
| 2026-06-10 | Kung Winston | 卖出 (S) | Common Stock, par value $0.0001 per share | 2,026 | USD 7.91 | USD 16,026 | SEC 申报 ↗ |
| 2026-06-10 | Jenkins John Kenneth | 卖出 (S) | Common Stock, par value $0.0001 per share | 4,800 | USD 7.91 | USD 37,968 | SEC 申报 ↗ |
| 2026-06-10 | Altmeyer Anne | 卖出 (S) | Common Stock, par value $0.0001 per share | 2,412 | USD 7.91 | USD 19,079 | SEC 申报 ↗ |
| 2026-06-03 | Saxena Nishant C | 买入 (P) | Common Stock, par value $0.0001 per share | 9,000 | USD 7.58 | USD 68,220 | SEC 申报 ↗ |
| 2026-06-02 | Saxena Nishant C | 买入 (P) | Common Stock, par value $0.0001 per share | 4,500 | USD 7.33 | USD 32,985 | SEC 申报 ↗ |
| 2026-05-21 | Saxena Nishant C | 奖励／授予 (A) | Common Stock, par value $0.0001 per share | 58,300 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-19 | Pfeiffenberger Brent | 奖励／授予 (A) | Common Stock, par value $0.0001 per share | 7,500 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-19 | Kung Winston | 奖励／授予 (A) | Common Stock, par value $0.0001 per share | 3,800 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-19 | Jenkins John Kenneth | 奖励／授予 (A) | Common Stock, par value $0.0001 per share | 3,800 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-19 | Jacques Rachelle Suzanne | 奖励／授予 (A) | Common Stock, par value $0.0001 per share | 3,800 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-19 | Ben Yong | 奖励／授予 (A) | Common Stock, par value $0.0001 per share | 3,800 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-19 | Altmeyer Anne | 奖励／授予 (A) | Common Stock, par value $0.0001 per share | 3,800 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-03-02 | Smethurst Dominic | 卖出 (S) | Common Stock, par value $0.0001 per share | 6,097 | USD 8.30 | USD 50,605 | SEC 申报 ↗ |
| 2026-02-17 | Hodgson Ian | 卖出 (S) | Common Stock, par value $0.0001 per share | 847 | USD 7.38 | USD 6,251 | SEC 申报 ↗ |
| 2026-02-13 | Moran Sean F. | 卖出 (S) | Common Stock, par value $0.0001 per share | 4,701 | USD 7.78 | USD 36,574 | SEC 申报 ↗ |
| 2026-02-13 | Cohen Yuval | 卖出 (S) | Common Stock, par value $0.0001 per share | 13,871 | USD 7.78 | USD 107,916 | SEC 申报 ↗ |
| 2026-02-03 | Smethurst Dominic | 卖出 (S) | Common Stock, par value $0.0001 per share | 3,285 | USD 8.09 | USD 26,576 | SEC 申报 ↗ |
| 2026-02-03 | Hodgson Ian | 卖出 (S) | Common Stock, par value $0.0001 per share | 2,415 | USD 8.09 | USD 19,537 | SEC 申报 ↗ |
| 2026-01-14 | Smethurst Dominic | 奖励／授予 (A) | Common Stock, par value $0.0001 per share | 28,365 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-14 | Moran Sean F. | 奖励／授予 (A) | Common Stock, par value $0.0001 per share | 28,082 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-14 | Hodgson Ian | 奖励／授予 (A) | Common Stock, par value $0.0001 per share | 28,365 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-14 | Cohen Yuval | 奖励／授予 (A) | Common Stock, par value $0.0001 per share | 50,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-12-11 | Chen Bihua; Cormorant Asset Management, LP; Cormorant Global Healthcare Master Fund, LP | 卖出 (S) | Common Stock | 30,029 | USD 11.46 | USD 344,132 | SEC 申报 ↗ |
| 2025-10-27 | Cohen Yuval | 卖出 (S) | Common Stock, par value $0.0001 per share | 8,973 | USD 17.14 | USD 153,797 | SEC 申报 ↗ |
| 2025-10-27 | Cohen Yuval | 期权行权／转换 (M) | Common Stock, par value $0.0001 per share | 8,973 | USD 4.26 | USD 38,225 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | CRBP |
| CIK | 0001595097 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 138 transaction lines from 2020-03-17 to 2026-09-14 47 P purchase lines · 37 S sale lines · 54 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.